OBI has submitted the IND application of a Phase I/II human clinical trial for OBI-902 TROP2 ADC to the US FDA

Date of occurrence of the event:2025/04/01 New drug name or code:OBI-902 TROP2 ADC Indication: OBI-902 is the first antibody-drug conjugate (ADC) developed using OBI’s proprietary GlycOBI ADC enabling technologies and targets TROP2. The asset has consistently shown superior antitumor activities across multiple tumor types in various animal models. GlycOBI is a glycan-based site-specific conjugation technology, […]